Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.77 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.70 |
| ▸ | CTSL | P07711 | 4/20 | 0.68 |
| ▸ | CTSS | P25774 | 1/20 | 0.68 |
| ▸ | CTSK | P43235 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | KLK7 | P49862 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236325 | 1.00 | TACR1 (0.77) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL621684 | 0.91 | TACR1 (0.78) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL1486155 | 0.91 | TACR1 (0.78) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL29400174 | 0.91 | TACR1 (0.78) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL5251038 | 0.91 | TACR1 (0.78) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL3644751 | 0.89 | TACR1 (0.72) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL9833806 | 0.89 | TACR1 (0.66) | TACR1SCN9ACTSLCTSSCTSK | |
| SCHEMBL8697113 | 0.89 | TACR1 (0.82) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL5355362 | 0.89 | TACR1 (0.82) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL29397912 | 0.89 | TACR1 (0.82) | TACR1CTSLCTSSCTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | TACR1 4684/4885SCN9A 3333/4885CTSL 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.